GlassScriptPhysician profile
Philip J Wang
NPI 1730517608
$1,766.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $426 · 2023: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.68 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $430.39 | 2021-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $240.42 | 2023 | Uzedy, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $189.46 | 2023 | Invega Sustenna, Spravato, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $151.38 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $132.57 | 2021-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.40 | 2022-2023 | |
| Axsome Therapeutics, INC. | $95.94 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $93.72 | 2023 | |
| Lundbeck LLC | $78.00 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $67.18 | 2022-2023 | Trintellix |
| Abbvie INC. | $59.67 | 2022-2023 | |
| Indivior INC. | $38.99 | 2022-2023 | Perseris |
| Supernus Pharmaceuticals, INC. | $29.55 | 2023 | Qelbree |
| Eisai INC. | $18.99 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.